Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...
Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results